This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Structuring patient assistance programs as independent non-profit foundations helps pharmaceuticalcompanies reduce regulatory and legal exposure while allowing for more holistic, patient-centered support. Lastly, PAPs that are directly managed by pharmaceuticalcompanies may also struggle with public image issues.
Download Issue PDF Articles in this issue Bolstering Health Technology Assessment With the Help of AI Changing the PAP Model Building Intelligent Pharma Supply Chain Management with Real-World Data Policy Whiplash? Haub School of Business.
How Recent Executive Orders Impact the Drug Pricing Landscape Nicholas Saraceno, Editor May 30th 2025 Podcast Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.
For submission consideration, manufacturers can petition the FDA for ANDA status if the requested change does not require safety or effectiveness studies. It is basically an essential copy, and the pharmaceuticalmanufacturer has to show bioequivalence to the reference product,” Soefje said. “If REFERENCE Soefje SA.
Download to learn about the causes of contamination and how to adapt your parenteral packaging – one potential source – to minimise the risk. Please check your inbox to download the Whitepaper. Mitigating the challenges Companies are taking actions to minimise the impact on their businesses. You will receive an email shortly.
Discover the leading patient adherence pharmaceuticalcompanies. Pharmaceutical Technology has listed the top patient adherence pharmaceuticalcompanies based on our intel, insights and decades-long expertise in the sector. Patient adherence.
This economic change impacts employment, income, industrial production, and more, and the pharmaceutical industry will not be exempt. While larger, more established pharmaceuticalcompanies may have the infrastructure and financial cushion to fall back on, SMEs need to tread carefully through these economic challenges.
Pharmaceutical wholesalers act as intermediaries between pharmaceuticalmanufacturers and retailers and facilitate the delivery of the right medicines in a timely, efficient, and secure manner. Wholesale distributors are responsible for guaranteeing product quality and preventing the influx of counterfeited drugs.
Commercial dose companies form a critical component of the pharmaceuticalmanufacturing industry’s value chain. The dose form manufacturing follows API manufacturing to produce the final dosage form (FDF such as tablets and injectables. Contract marketing of commercial doses.
The pharmaceutical industry requires specialised and cost-effective commercial packaging solutions to improve efficiency and preserve the integrity of products through the entire supply chain, from primary packaging and labelling to shipping, delivery, storage and distribution to end users.
Contract marketing companies support pharmaceuticalcompanies in creating, improving, and maintaining their brand, as well as reducing risk, and ensuring better product placement in the market. Identifying the top commercial dose (non-sterile) companies in contract marketing.
Tablet manufacturing, which is the most common OSD form, takes an API dry powder ingredient and compresses it to form tablets, which can be coated or uncoated. Compared to other dosage forms, tablets are simpler to manufacture, package, and transport. Please check your email to download the Webinar.
Container Closure Integrity Testing (CCIT) is used to evaluate the ability of a pharmaceutical’s primary packaging to protect the sterility of its contents. On a regular basis, pharmaceuticalmanufacturers are performing CCIT during commercial production to ensure that packaging processes are operating as they should.
Despite the current emphasis on biologic medicines, small molecule drugs still dominate the pharmaceuticalmanufacturing world. Within the small molecule landscape, several trends are shaping the industry’s future, one of the most notable being the rise of high-potency active pharmaceutical ingredients (HPAPIs). Free Whitepaper.
In the 1990s, generic pharmaceuticalcompanies in the European Union (EU) offshored the manufacturing of active pharmaceutical ingredients (API) primarily to China. Moreover, US Pharmacopeia issued the first-ever Medicine Supply Map to find and quantify risks in upstream pharmaceutical supply chains across the country.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content